RecruitingPhase 1NCT06656494

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Intervention: ICP-248(drug)
Enrollment: 266 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2028

Study locations (18)

Yale University, Yale Cancer Center, New Haven, Connecticut, United States
NYU Langone Health, New York, New York, United States
St Vincent's Hospital, Sydney, New South Wales, Australia
Royal Perth Hospital, Perth, Western Australia, Australia
Anhui Provincial Hospita, Hefei, Anhui, China
Peking University People's Hospital, Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
The First Hospital of Jilin University, Changchun, Jilin, China
Shengjing Hospital of China Medical University, Shengyang, Liaoning, China
+3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06656494 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease →

← Back to all trials